ADC Therapeutics S.A.
NYSE:ADCTBiotechnology
-$0.02 today
- Market cap
- $192.71M
- Beta
- 1.77
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$0.89
Volume 1.17M
Average 1.68M
ADCT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
ADC Therapeutics S.A.NYSE: ADCT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $32.97M (cash outflow) fell 14.6% year over year, behind the -8.6% change in trailing-twelve-month net income. Sequentially, it rose 414.4% from the prior quarter. Over 3 fiscal years it compounded at -3.2% a year.
Context
- Net income amounted to 175.3% of revenue in FY2025, down 47.5 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$88.63M (-37.9%) for the fiscal year ending Dec 2026, a slowdown from the -9.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$32.97M+414.4% QoQ
- Last fiscal yearDec 2025
- -$142.62M-9.6% YoY
- LTMMar 2026
- -$136.99M-8.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -14.6% | -40.7% | -26.1 pp |
| 1 year | -9.6% | -37.9% | -28.2 pp |
| 3-year CAGR | -3.2% | -31.4% | -28.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (142.62M) USD
- Year-over-year change
- +9.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (142.62M) | +9.6% |
| FY2024 | 2024-12-31 | (157.85M) | +34.2% |
| FY2023 | 2023-12-31 | (240.05M) | -52.8% |
| FY2022 | 2022-12-31 | (157.13M) | +31.7% |
| FY2021 | 2021-12-31 | (230.03M) | — |
Net Income vs competitors
How ADCT compares with its peers on the latest reported figures
- ADCT's LTM Mar 2026 net income of $136.99M is the 6th largest of the 10 companies compared; the peer median is $160.9M.
- Its year-over-year change of -8.6% is the 7th highest of 10, against a peer median of +7.2%.
- Net income amounts to 173.0% of revenue for ADCT, versus a peer median of 388.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $438.96M | +92.9% | +29.5% | 5933.5% |
| LTM Mar 2026 | $288.97M | +21.3% | +24.5% | 312.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $222.39M | -13.8% | +21.9% | — |
| LTM Mar 2026 | $218.8M | +7.2% | +24.8% | 344.6% | |
| LTM Mar 2026 | $160.9M | -8.8% | +9.2% | 182.3% | |
| LTM Mar 2026 | $136.99M | -8.6% | -3.2% | 173.0% | |
| LTM Mar 2026 | $103.82M | +3.1% | -8.5% | 5605.9% | |
| LTM Mar 2026 | $81.36M | +148.9% | -73.6% | 822.4% | |
| LTM Mar 2026 | $64.01M | +294.9% | +34.1% | 433.1% | |
| LTM Mar 2026 | $26.09M | -85.3% | -21.0% | 37.5% | |
| Peer median (excluding ADCT) | $160.9M | +7.2% | +21.9% | 388.8% | |
Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (230.03M) | (157.13M) | (240.05M) | (157.85M) | (142.62M) |
| Depreciation & Amortization | 2.63M | 5.74M | 3.27M | 3.28M | 1.88M |
| Deferred Income Tax | (26.05M) | 0 | 37.1M | 0 | 0 |
| Stock-Based Compensation | 60.48M | 50.64M | 13.5M | 6.57M | 6.91M |
| Change in Working Capital | (15.71M) | (49.04M) | 44.27M | 3.83M | (25.36M) |
| Accounts Receivables | (30.22M) | (42.75M) | 47.79M | 4.77M | (8.79M) |
| Inventory | (3.02M) | (9.65M) | (5.71M) | (3.73M) | (2.38M) |
| Accounts Payables | 6.8M | 310K | 3.17M | 2.46M | (9.04M) |
| Other Working Capital | 10.73M | 3.37M | (979K) | 321K | (5.15M) |
| Other Non-Cash Items | (24.7M) | 11.48M | 23.23M | 20.34M | 18.02M |
| Operating Cash Flow | (233.38M) | (138.31M) | (118.69M) | (123.84M) | (141.17M) |
| Capital Expenditures | (6.38M) | (687K) | (3.22M) | (867K) | (264K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 659K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (3.24M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (6.67M) | (687K) | (3.22M) | (867K) | 395K |
| Debt Repayment | 48.61M | (2.71M) | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 60.51M | 152.46M |
| Common Stock Repurchased | 0 | (1.32M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 218.78M | 3.13M | 73.88M | 36.55M | (1.51M) |
| Financing Cash Flow | 267.39M | (897K) | 73.88M | 97.05M | 150.95M |
| Effect of Forex Changes | 6K | (208K) | 184K | (83K) | 305K |
| Net Change in Cash | 27.35M | (140.1M) | (47.84M) | (27.73M) | 10.47M |
| Free Cash Flow | (239.75M) | (139M) | (121.9M) | (124.7M) | (141.44M) |
ADC Therapeutics S.A.
NYSE:ADCT
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.